EP0620739A4 - Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists. - Google Patents

Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.

Info

Publication number
EP0620739A4
EP0620739A4 EP93921562A EP93921562A EP0620739A4 EP 0620739 A4 EP0620739 A4 EP 0620739A4 EP 93921562 A EP93921562 A EP 93921562A EP 93921562 A EP93921562 A EP 93921562A EP 0620739 A4 EP0620739 A4 EP 0620739A4
Authority
EP
European Patent Office
Prior art keywords
necrosis factor
tumor necrosis
factor antagonists
treating tnf
dependent inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93921562A
Other versions
EP0620739A1 (en
Inventor
Craig A Smith
Cindy A Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0620739(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of EP0620739A1 publication Critical patent/EP0620739A1/en
Publication of EP0620739A4 publication Critical patent/EP0620739A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP93921562A 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists. Withdrawn EP0620739A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94623692A 1992-09-15 1992-09-15
US946236 1992-09-15
PCT/US1993/008666 WO1994006476A1 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists

Publications (2)

Publication Number Publication Date
EP0620739A1 EP0620739A1 (en) 1994-10-26
EP0620739A4 true EP0620739A4 (en) 1997-01-15

Family

ID=25484181

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93921562A Withdrawn EP0620739A4 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.

Country Status (8)

Country Link
EP (1) EP0620739A4 (en)
JP (1) JPH07504203A (en)
KR (1) KR100232688B1 (en)
AU (1) AU670125B2 (en)
CA (1) CA2123593C (en)
NO (1) NO941780L (en)
NZ (1) NZ256293A (en)
WO (1) WO1994006476A1 (en)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE289350T1 (en) * 1989-04-21 2005-03-15 Amgen Inc TNF RECEPTOR, TNF BINDING PROTEINS AND DNA CODING THEREOF
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
JPH09508140A (en) * 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー Pharmaceutical composition containing chimeric TNF binding protein
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
JPH11500308A (en) * 1995-02-03 1999-01-12 ジー．ディー．サール アンド カンパニー New c-MPL ligand
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
DK0839046T3 (en) 1995-07-14 2002-02-18 Applied Research Systems TNF receptor and steroid hormone in a combination therapy
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
TR199802238T2 (en) * 1996-05-08 1999-02-22 F. Hoffmann-La Roche Ag Treatment of asthma with TNFR-Ig.
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP2001513754A (en) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Combination therapy using TNF binding proteins for treating TNF-mediated diseases
SI0942740T1 (en) * 1996-12-06 2003-12-31 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0980258A1 (en) * 1997-05-12 2000-02-23 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
WO1999003998A1 (en) * 1997-07-17 1999-01-28 The Regents Of The University Of Michigan Methods and compositions for tumor reduction
WO2000002902A1 (en) * 1998-07-13 2000-01-20 Gill Parkash S Novel inhibitors of angiogenesis and tumor growth
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE372126T1 (en) * 1998-11-05 2007-09-15 Omeros Corp FLUSH SOLUTION AND METHOD FOR PAIN RELIEF AND ANTI-INFLAMMATORY
TR200504220T2 (en) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins.
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
EP1165116A1 (en) * 1999-04-02 2002-01-02 Immunex Corporation Use of soluble tumor necrosis factor receptor for treating heart failure
DE60040147D1 (en) * 1999-05-28 2008-10-16 Targeted Genetics Corp METHODS AND COMPOSITIONS FOR REDUCING TUMOR NEKROSIS FACTOR MIRROR (TNF) IN TNF ASSOCIATED DISEASES
EP1939300A1 (en) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
RU2271825C2 (en) * 1999-07-21 2006-03-20 Омерос Корпорейшн Solutions and methods for inhibiting pain, cartilage inflammation and destruction
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
AU783682B2 (en) 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040219142A1 (en) 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
MXPA05001758A (en) * 2002-08-16 2005-08-19 Wyeth Corp Compositions and methods for treating rage-associated disorders.
JP2006500927A (en) * 2002-09-13 2006-01-12 ザ・ユニバーシティ・オブ・クイーンズランド Gene expression system based on codon translation efficiency
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
JP4980048B2 (en) 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム Liquid formulation of tumor necrosis factor binding protein
US20080241884A1 (en) * 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
TWI439284B (en) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 Multiple variable dose therapy for the treatment of TNFα-related disorders
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
DK1817340T3 (en) * 2004-11-12 2012-08-13 Xencor Inc FC VARIATIONS WITH CHANGED BINDING TO FCRN
AU2006230419A1 (en) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
CN102961746B (en) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 The purposes of TNF α inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
NZ567286A (en) 2005-11-01 2012-03-30 Abbott Biotechnolgy Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US7972599B2 (en) 2006-03-20 2011-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
KR20140071452A (en) 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 Antibody purification
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2703010A3 (en) 2006-04-10 2014-08-06 AbbVie Biotechnology Ltd Uses and compositions for treatment of rheumatoid arthritis
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd Uses and compositions for treatment of psoriatic arthritis
KR101396797B1 (en) 2006-06-30 2014-05-26 애브비 바이오테크놀로지 리미티드 Automatic injection device
JP2010501622A (en) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Purification method of Fc-fusion protein
DK2061803T4 (en) 2006-08-28 2022-12-05 Ares Trading Sa PROCEDURE FOR PURIFICATION OF FC-CONTAINING PROTEINS
EA017733B1 (en) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. PROCESS FOR THE PURIFICATION OF Fc-FUSION PROTEINS
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2010506955A (en) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment of demyelinating disorders with soluble lymphotoxin beta receptor
CA2666981A1 (en) * 2006-10-20 2008-05-02 Ercole Biotech, Inc. Soluble tnf receptors and their use in treatment of disease
EP2679996A1 (en) 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd Methods for treating juvenile idiopathic arthritis
EP2158210B1 (en) 2007-06-14 2015-12-09 Galactica Pharmaceuticals, Inc. Rage fusion proteins
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
WO2010018444A2 (en) * 2008-08-12 2010-02-18 Avesthagen Limited An expression vector and a method thereof
MX2011007030A (en) 2008-12-30 2011-07-20 Centocor Ortho Biotech Inc Serum markers predicting clinical response to anti-tnf antibodies in patients with ankylosing spondylitis.
KR101721906B1 (en) 2009-04-29 2017-03-31 애브비 바이오테크놀로지 리미티드 Automatic injection device
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JP2013512674A (en) 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Compositions and methods for increasing the serum half-life of an Fc fusion protein
US20110150891A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of Treating Interstitial Cystitis
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
HRP20171939T1 (en) 2010-01-15 2018-03-23 Kirin-Amgen, Inc. ANTIBODY FORMULATION AND THERAPY REGIMES
JP2013518590A (en) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド Methods and compositions for predicting responsiveness to treatment with a TNF-α inhibitor
EP3360596A1 (en) 2010-04-21 2018-08-15 AbbVie Biotechnology Ltd. Wearable automatic injection device for controlled delivery of therapeutic agents
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
HRP20181598T1 (en) 2010-06-03 2018-11-30 Abbvie Biotechnology Ltd USE AND PREPARATIONS FOR THE TREATMENT OF HYDRADENITIS SUPPURATIVA (HS)
FR2962335B1 (en) 2010-07-12 2013-01-18 Cll Pharma USE OF PAT NONAPEPTIDE IN THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES
WO2012019099A2 (en) 2010-08-05 2012-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Follistatin-like-protein-1 as a biomarker for inflammatory disorders
MX360402B (en) 2011-01-24 2018-10-31 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces.
BR112013023967A2 (en) 2011-03-18 2016-01-19 Abbvie Inc systems, devices and methods for assembling automatic injection devices and subsets thereof
WO2012135524A1 (en) 2011-03-29 2012-10-04 Abbott Laboratories Improved shroud deployment in automatic injection devices
WO2012145752A2 (en) 2011-04-21 2012-10-26 Abbott Laboratories Wearable automatic injection device for controlled administration of therapeutic agents
UY34105A (en) 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING SERIAL HALF LIFE
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Composition for treating rheumatoid arthritis and method of use thereof
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
HK1200718A1 (en) 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with sodium chloride
KR101525919B1 (en) * 2012-05-11 2015-06-03 가톨릭대학교 산학협력단 Bispecific antibody based on TNFR2 for preventing and traeating autoimmune disease
EA031324B1 (en) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Correctly folded etanercept in high purity and excellent yield
US20170174772A1 (en) 2014-03-31 2017-06-22 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
AU2015371381A1 (en) 2014-12-22 2017-07-20 Ares Trading S.A. Liquid pharmaceutical composition
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
AU2017248354A1 (en) 2016-04-08 2018-10-04 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
EP3554342B1 (en) 2016-12-14 2024-07-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
JOP20190162A1 (en) 2016-12-30 2019-06-27 Biocad Joint Stock Co Aqueous Pharmaceutical Composition of a Recombinant Monoclonal Antibody to TNF?
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
AU2019299444A1 (en) 2018-07-03 2021-01-14 Novartis Ag Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist
AU2019329958B2 (en) 2018-08-29 2025-05-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
BR112021014377A2 (en) 2019-01-31 2021-12-28 Regeneron Pharma Compositions and methods for treating juvenile idiopathic arthritis
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
CN110964119A (en) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 Anti-malarial dimeric immunoadhesin, pharmaceutical composition and use
JP7688150B2 (en) 2020-12-09 2025-06-03 エイチケー イノ．エヌ コーポレーション Anti-OX40L antibody, bispecific antibody of anti-OX40L and anti-TNFα, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003553A1 (en) * 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
WO1992013095A1 (en) * 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
CA2145192A1 (en) * 1992-09-22 1994-03-31 Gail Underiner Novel epoxide-containing compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003553A1 (en) * 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
WO1992013095A1 (en) * 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOHLER K M ET AL: "COUNTERACTING THE EFFECTS OF TNF WITH SOLUBLE TNF RECEPTORS.", KEYSTONE SYMPOSIUM ON CYTOKINES AND CYTOKINE RECEPTORS: FROM CLONING TO THE CLINIC, KEYSTONE, COLORADO, USA, JANUARY 31-FEBRUARY 7, 1993. J CELL BIOCHEM SUPPL 0 (17 PART B). 1993. 56, XP002015787 *
MOHLER K M ET AL: "IMMUNOTHERAPEUTIC POTENTIAL OF SOLUBLE CYTOKINE RECEPTORS IN INFLAMMATORY DISEASE.", 1992 MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY (FASEB), PART I, ANAHEIM, CALIFORNIA, USA, APRIL 5-9, 1992. FASEB (FED AM SOC EXP BIOL) J 6 (4). 1992. A1123, XP002015786 *
See also references of WO9406476A1 *

Also Published As

Publication number Publication date
KR100232688B1 (en) 1999-12-01
EP0620739A1 (en) 1994-10-26
NO941780L (en) 1994-07-15
AU670125B2 (en) 1996-07-04
CA2123593C (en) 2000-03-14
NZ256293A (en) 1997-06-24
NO941780D0 (en) 1994-05-11
CA2123593A1 (en) 1994-03-31
JPH07504203A (en) 1995-05-11
WO1994006476A1 (en) 1994-03-31
AU4920993A (en) 1994-04-12

Similar Documents

Publication Publication Date Title
EP0620739A4 (en) Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
GB2265399B (en) Horizontal well treatment method
GB2267508B (en) Water treatment method
ZA93811B (en) Methods of treating inflammatory dermatoses.
ZA937340B (en) Method of combining polymers
GB9215042D0 (en) Microwave treatment apparatus
AU3973793A (en) Method of treating cancer
AU7128494A (en) Gelatinase antagonists used for treating cancer
ZA918116B (en) Inhibitors for the formation of tumor necrosis factor,processes for the preparation thereof and the use thereof
GB9218027D0 (en) Novel method of treatment
GB9217998D0 (en) Methods of treating cancer
EP0654996A4 (en) Methods of treating psoriasis employing substituted azaspiranes.
EP0609358A4 (en) Methods for treatment of hyperlipidemia using azaspiranes.
GB9202196D0 (en) Method of treatment
EP0609335A4 (en) Methods for the treatment of hyperlipidemia using azaspiranes.
ZA932731B (en) Method of treating gar-transformylase-dependent tumors
GB9201391D0 (en) Method of treatment
EP0752856A4 (en) Methods of treating hyperlipidemia
EP0705104A4 (en) Method of cancer treatment
HK1012276A (en) Methods of treating psoriasis employing substituted azaspiranes
ZA922012B (en) New method of treatment for prostatic cancer
GB9218188D0 (en) Method of treatment
GB9223252D0 (en) Method of treatment
GB9202698D0 (en) Method of treatment
GB9207275D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19961127

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19970228

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980103